Meta-analysis of 62 RCTs (24,518 patients) in metastatic renal cell carcinoma: PFS (r = 0.52) and ORR (r = −0.59) showed only moderate trial-level correlation with overall survival, not consistent enough to reliably predict OS benefit.
Meta-analysisn = 24,518
Leong et al. Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis